Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug aimed at lung cancer shows promise in early trial

NCT ID NCT05577715

Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested an experimental drug called MORAb-202 in 31 people with a type of advanced lung cancer (non-small cell lung cancer adenocarcinoma) that had gotten worse after other treatments. The drug is designed to target and kill cancer cells while sparing healthy ones. The trial was stopped early, but researchers were looking at how safe the drug is and whether it can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
MORAb-202 (Farletuzumab ecteribulin)
What this could lead to
If it works, this could point toward a new treatment option for people with a certain type of advanced lung cancer that has stopped responding to other therapies.
What could go wrong
This was a small, early-phase trial that was terminated early, so results are limited. The drug may cause side effects and may not shrink tumors or improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

31 people

The number who actually took part.

Started

Nov 2022

Finished

Aug 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histologically or cytologically documented metastatic NSCLC AC (as defined by the 8th International Association for the Study of Lung Cancer Classification). * Measurable target disease assessed by the investigator according to RECIST 1.1. * Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 Exclusion Criteria: * NSCLC histologies other than AC (ie, squamous cell carcinoma, large cell carcinoma). * Significant third-space fluid retention (eg, ascites or pleural effusion) that requires repeated drainage. * Prior pneumonectomy. Prior lobectomy and segmentectomy are allowed \> 12 months before treatment. * Recent chest radiotherapy. Participants with chest or chest wall radiation may be permitted if chest radiation is documented \> 6 months before starting study treatment. Other protocol-defined inclusion/exclusion criteria apply.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Carcinoma, non-small-cell lung are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

adenocarcinoma non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Carcinoma, non-small-cell lung

Contacts and locations

Locations

  • Henry Ford Hospital

    Detroit, Michigan, 48202-2608, United States

  • Local Institution - 0001

    Marietta, Georgia, 30060, United States

  • Local Institution - 0002

    Kansas City, Missouri, 64132, United States

  • Local Institution - 0005

    Louisville, Kentucky, 40241-2832, United States

  • Local Institution - 0007

    Orange, California, 92868-3201, United States

  • Local Institution - 0010

    Orange City, Florida, 32763-8316, United States

  • Local Institution - 0011

    Charlotte, North Carolina, 28207, United States

  • Local Institution - 0012

    Ballarat Central, Victoria, 3350, Australia

  • Local Institution - 0014

    Toulon, 83056, France

  • Local Institution - 0015

    Suresnes, 92151, France

  • Local Institution - 0017

    Rouen, 76000, France

  • Local Institution - 0018

    Madrid, 28041, Spain

  • Local Institution - 0019

    Majadahonda (Madrid), M, 28222, Spain

  • Local Institution - 0020

    Málaga, MA, 29010, Spain

  • Local Institution - 0021

    Barcelona, 08036, Spain

  • Local Institution - 0022

    Murdoch, Western Australia, 6150, Australia

  • Local Institution - 0023

    Santiago, 7500921, Chile

  • Local Institution - 0025

    Barcelona, 08035, Spain

  • Local Institution - 0026

    Santiago de Compostela, 15706, Spain

  • Local Institution - 0027

    Recoleta, 8420383, Chile

  • Local Institution - 0028

    Providencia, SA, 7500653, Chile

  • Local Institution - 0030

    Independencia, 8380456, Chile

  • Local Institution - 0031

    Seville, 41013, Spain

  • Local Institution - 0033

    Fairfax, Virginia, 22031-4629, United States

  • Local Institution - 0034

    Arlington, Texas, 76012-2510, United States

  • Local Institution - 0035

    Lone Tree, Colorado, 80124, United States

  • Local Institution - 0036

    Roeselare, 8800, Belgium

  • Local Institution - 0038

    Villejuif, 94805, France

  • Local Institution - 0039

    Mons, WHT, 7000, Belgium

  • Local Institution - 0040

    Wollongong, NS, 2500, Australia

  • Local Institution - 0043

    Clermont, Florida, 34711-6699, United States

  • Local Institution - 0044

    Silver Spring, Maryland, 20904-7917, United States

  • Local Institution - 0045

    Flower Mound, Texas, 75028-1713, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.